BSD Medical Shares Pop, Isis Receives Payment From Alnylam: Healthcare Business Wrap

Shares of BSD Medical Corporation (NASDAQ:BSDM) pop following the report of clinical data demonstrating a threefold increase in tumor destruction in patients suffering with advanced rectal cancer after using its its BSD-2000 Hyperthermia System along with to preoperative radiochemotherapy. Additionally, the treatment left no evidence of a viable tumor in a statistically significant number of patients.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Raised uncertainty around the reimbursement environment for skilled nursing facilities leading up to the Presidential election, is being blamed for a lack of upside catalysts for assisted living facility manager Omega Healthcare Investors (NYSE:OHI), which was downgraded Tuesday to Hold at
Jefferies.

Isis Pharmaceuticals (NASDAQ:ISIS) announces that it will receive $1.1 million from Alnylam Pharmaceuticals (NASDAQ:ALNY) representing its portion of the upfront fees in the latter’s recently announced collaboration with Genzyme. Further, Isis also possesses the potential to receive royalty payments and a portion of future milestone payments. Thus far in 2012, the firm has earned $2.7 million from Alnylam from licenses that were supported by patents owned by Isis.

Don’t Miss: Here’s Why Pharma Stocks are in Play.